Rheological Behavior of a New Mucoadhesive Oral Formulation Based on Sodium Chondroitin Sulfate, Xyloglucan and Glycerol
Source abstract
Abstract
Background: The study aimed at assessing the mucoadhesive properties and the barrier effect of a formulation, labelled as AL2106, containing sodium chondroitin sulfate (ChS), xyloglucan from tamarind seed extract, and glycerol, by evaluating the capacity to adhere to a layer of mucin, the rheological synergism and the barrier effect in comparison to the marketed Esoxx One medical device. AL2106 is a medical device distributed by Alfasigma SpA, Italy with REF FTP57 (Manufacturer: Labomar SpA); it is analogous to Esoxx One medical device: the two products are drinkable solutions that, after swallowing, adhere to the esophageal mucosa, protecting it from the corrosive effect of the gastric acid reflux. AL2106 has been conceived to be better performing in terms of duration of the barrier effect compared to Esoxx One. Methods: The mucoadhesive properties, rheological behavior, buffering capacity against acidity, and film-forming ability with the resultant protecting effect on esophagus mucosa (caffeine permeation test) was compared between the two products. Results: The mucoadhesivity of the formulations was shown in vitro: both remained adherent to a mucin layer, also when the support was rotated by 90°, and when the film layer was washed with water, intended to simulate the washout due to swallowing. AL2106 showed a good buffering efficacy, being able to absorb at least 50% of its weight of 0.03 M HCl while maintaining the pH above 4. The film-forming effect and barrier properties of AL2106 and Esoxx One were confirmed by an in vitro study on reconstructed human esophageal epithelium. A greater film-forming efficacy of AL2106, lasting for at least 5 h, than Esoxx One was observed. Noteworthy, the barrier function of esophageal tissues was shown to be preserved after the application of both formulations. Conclusions: The combination of ChS with the mucoadhesive glycerol−xyloglucan complex and other excipients, which contribute to the barrier effect and to mucoadhesion, contained in AL2106, allowed a longer-lasting protective effect than Esoxx One, proving its effectivity and safety for oral use.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Dysphagia Assessment and Management · Advanced Drug Delivery Systems · Gastroesophageal reflux and treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Labomar SpA, via Nazario Sauro 35/I, Istrana, 31036 Treviso, Italy
Alfasigma SpA, via Ragazzi del ’99, 40133 Bologna, Italy
Department of Drug and Health Sciences, University of Catania, Viale A. Doria, 6, 95125 Catania, Italy
References (42)
Show source-provided references
1. (Review Team): World Gastroenterology Organisation Global Guidelines10.1097/MCG.0000000000000854 ↗
2. Wang, Y.K., Hsu, W.H., Wang, S.S., Lu, C.Y., Kuo, F.C., Su, Y.C., Yang, S.F., Chen, C.Y., Wu, D.C., and Kuo, C.H. (2013). Current pharmacological management of gastresophageal reflux disease. Gastroenterol. Res. Pract., 983653.10.1155/2013/983653 ↗
3. Drugs for improving esophageal mucosa defense: Where are we now and where are we going?
4. Chondroitin sulfate: A potential biodegradable carrier for colon-specific drug delivery10.1016/0378-5173(92)90054-6 ↗
5. Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis
6. The pathobiology of osteoarthritis and the rationale for using the chondroitin sulfate for its treatment10.2174/1568008043339929 ↗
7. Controlled release of platelet-derived growth factor-BB from chondroitin sulfate–chitosan sponge for guided bone regeneration10.1016/S0168-3659(00)00232-7 ↗
8. Acidic glycosaminoglycans in human esophagus tissue10.1620/tjem.127.273 ↗
9. Protective effect of chondroitin sulfate from sea cucumber against alcohol-induced gastric ulcer in rats
10. Fixed combination of hyaluronic acid and chondroitin-sulphate oral formulation in a randomized double blind, placebo controlled study for the treatment of symptoms in patients with non-erosive gastresophageal reflux
11. Synthesis, characterization and evaluation of thiolated tamarind seed polysaccharide as a mucoadhesive polymer10.1016/j.carbpol.2012.07.028 ↗
12. Pressure cell assisted solubilization of xyloglucans: Tamarind seed polysaccharide and detarium gum10.1021/bm0257659 ↗
13. Novel tamarind seed polysaccharide-alginate mucoadhesive microspheres for oral gliclazide delivery: In vitro-in vivo evaluation10.3109/10717544.2012.657717 ↗
14. Gelation of xyloglucan in water/alcohol systems10.1023/B:CELL.0000025427.60557.40 ↗
15. Thiolated xyloglucan: Synthesis, characterization and evaluation as mucoadhesive in situ gelling agent10.1016/j.carbpol.2012.08.077 ↗
16. Evidence for bioadhesive effects of polysaccharides and polysaccharide-containing herbs in an ex vivo bioadhesion assay on buccal membranes10.1055/s-2000-11118 ↗
17. Synergistic interaction between TS-polysaccharide and hyaluronic acid: Implications in the formulation of eye drops10.1016/j.ijpharm.2010.05.031 ↗
18. Evaluation of structure and assembly of xyloglucan from tamarind seed (Tamarindus indica L.) with Atomic Force Microscopy10.1007/s11483-015-9395-2 ↗
19. Gnessi, L., Bacarea, V., Marusteri, M., and Piqué, N. (2015). Xyloglucan for the treatment of acute diarrhea: Results of a randomized, controlled, open-label, parallel group, multicentre, national clinical trial. BMC Gastroenterol., 15.10.1186/s12876-015-0386-z ↗
20. Xyloglucan for the treatment of acute gastroenteritis in children: Results of a randomized controlled, clinical trial
21. Preparation and evaluation of stomatitis film using xyloglucan containing loperamide10.1248/cpb.c15-00926 ↗
22. Cranberry xyloglucan structure and inhibition of Escherichia coli adhesion to epithelial cells10.1021/acs.jafc.5b00730 ↗
23. Natural products as aids for protecting the skin’s immune system against UV damage
24. Effect of xyloglucan (tamarind seed polysaccharide) on conjunctival cell adhesion to laminin and on corneal epithelium wound healing10.1177/112067210001000112 ↗
25. Nanoparticles made from xyloglucan-block-polycaprolactone copolymers: Safety assessment for drug delivery10.1093/toxsci/kfv114 ↗
26. Bottoni, G., Maffei, P., Sforzini, A., Federici, M., Caramella, C., Rossi, S., and Viscomi, G.C. (2008). Mucoadhesive Xyloglucan-Containing Formulations Useful in Medical Devices and Pharmaceutical Presentations. (1,898,876,B1), European Patent.
27. Barrier effect of a new topical agent on damaged esophageal mucosa: Experimental study on an ex vivo swine model10.2147/CEG.S269568 ↗
28. A simple rheological method for the in vitro assessment of mucin-polymer bioadhesive bond strength10.1023/A:1015812615635 ↗
29. Meloni, M., Dalla Valle, P., Cappadoro, M., and de Wever, B. (2002, January 16–19). The importance of multiple endpoint analysis (MEA) using reconstituted human tissue models for irritation and biocompatibility assays. Proceedings of the INVITOX 2002: 12th International Workshop on In Vitro Toxicology, Formia, Italy.
30. Rheological and tensile tests for the assessment of polymer–mucin interactions
31. The basic and underlying mechanisms of mucoadhesion10.1016/j.addr.2005.07.001 ↗
32. Wu, S. (1982). Formation of adhesive bond. Polymer Interface and Adhesion, Marcel Dekker Inc.
33. The use of mucoadhesive polymers in buccal drug delivery10.1016/j.addr.2005.07.003 ↗
34. Oral cavity as a site for bioadhesive drug delivery10.1016/0169-409X(94)90026-4 ↗
35. Hydrophobic binding properties of bovine gallbladder mucin10.1016/S0021-9258(20)71335-9 ↗
36. Mucin biophysics10.1146/annurev.ph.57.030195.003223 ↗
37. Bueno, L., Theodorou, V., and Sekkal, S. (2014, January 18–22). Xyloglucan: A new agent to protect the intestinal mucosa and to prevent bacterially mediated alteration of tight junction permeability. Proceedings of the 22nd United European Gastroenterology (UE.G.) Week, Vienna, Austria. Abstract P1675.
38. Influence of mucin type on polymer-mucin rheological interactions10.1016/0142-9612(95)98903-R ↗
39. Evaluation of acid neutralizing and buffering capacities of selected antacids in Ghana
40. Non-animal models of epithelial barriers (skin, intestine and lung) in research, industrial applications and regulatory toxicology10.14573/altex.1510051 ↗
41. Zuang, V., Schäffer, M., Tuomainen, A.M., Amcoff, P., Bernasconi, C., Bremer, S., Casati, S., Castello, P., Coecke, S., and Corvi, R. (2020, November 18). EURL ECVAM Progress Report on the Development, Validation and Regulatory Acceptance of Alternative Methods (2010–2013). Available online: http://ihcp.jrc.ec.europa.eu/.
42. TEER measurement techniques for in vitro barrier model systems10.1177/2211068214561025 ↗